newsfilter
← Latest News
GlobeNewswire·

First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis

ZUG, Switzerland, August 24th, 2026 -- Oculis Holding AG (NASDAQ:OCS) ("Oculis"), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in